TAXOTERE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TAXOTERE (TAXOTERE).
Taxotere (docetaxel) is a semisynthetic taxane that promotes microtubule assembly and inhibits depolymerization, leading to stabilization of microtubules and disruption of mitotic cell division. This results in cell cycle arrest at G2/M phase and apoptosis in cancer cells.
| Metabolism | Docetaxel is primarily metabolized by the hepatic cytochrome P450 enzyme system, specifically CYP3A4 and CYP3A5. It undergoes oxidation to form several metabolites, with the major metabolite being an inactive pyranose ring-opened form. |
| Excretion | Following hepatic metabolism, elimination is primarily via biliary/fecal excretion (approximately 75% of dose as metabolites and unchanged drug), with renal excretion accounting for about 10% (primarily as metabolites). |
| Half-life | Terminal elimination half-life is approximately 11–13 hours, with a mean of 11.1 hours. This supports a 3-week dosing interval. |
| Protein binding | Approximately 94–97% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein (AAG). |
| Volume of Distribution | Volume of distribution at steady state is 113–227 L/m² (approximately 2.5–4.5 L/kg based on average BSA), indicating extensive extravascular distribution and tissue binding. |
| Bioavailability | Only available intravenously; oral bioavailability is negligible (<10%) due to poor absorption and extensive first-pass metabolism, and is not clinically used. |
| Onset of Action | Following intravenous administration, clinical antitumor effect onset is typically observed within 2–3 weeks, corresponding to the time to myelosuppression nadir and tumor response. |
| Duration of Action | Duration of action is approximately 3 weeks, consistent with the dosing interval. Myelosuppression typically resolves within 21 days. |
| Action Class | Antimicrotubule agents- Taxanes |
| Brand Substitutes | Docax 80mg Injection, Relidoce 80mg Injection, Chemodoc 80mg Injection, Zenotere 80mg Injection, Innotubilin 80mg Injection, Docax 20mg Injection, Relidoce 20mg Injection, Docecad 20mg Injection, Innotubilin 20mg Injection, Doxel 20mg Injection |
75 mg/m² intravenously over 1 hour every 3 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl >30 mL/min); not studied in severe renal impairment (CrCl ≤30 mL/min). |
| Liver impairment | Child-Pugh Class A: 75 mg/m²; Child-Pugh Class B: Dose reduction recommended, but specific dose not established; contraindicated in Child-Pugh Class C. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor for increased toxicity, especially neutropenia, neuropathy, and fatigue. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TAXOTERE (TAXOTERE).
| Breastfeeding | Not recommended during breastfeeding. No data on milk excretion; based on low molecular weight (807.9 g/mol), protein binding (~94%), and long half-life (11-21 hours), docetaxel is likely to be transferred into breast milk. M/P ratio unknown. Risk of neonatal immunosuppression, neutropenia, and growth suppression. Discontinue breastfeeding for at least 1 week after last dose. |
| Teratogenic Risk | Taxotere (docetaxel) is a taxane antineoplastic agent classified as Pregnancy Category D. First trimester: High risk of embryotoxicity, fetal malformations (neural tube defects, skeletal anomalies) and spontaneous abortion based on animal studies and human case data, as it inhibits microtubule assembly critical for cell division. Second/Third trimesters: Associated with intrauterine growth restriction, oligohydramnios, prematurity, and neonatal pancytopenia. Avoid use unless maternal benefit outweighs fetal risk. |
■ FDA Black Box Warning
TOXICITY: Taxotere should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. Fatalities have occurred due to severe hypersensitivity reactions, severe fluid retention, and severe neutropenia. Patients with elevated liver function tests (bilirubin > ULN, or AST/ALT > 1.5 x ULN concomitant with ALP > 2.5 x ULN) are at increased risk for severe and fatal toxicities and should not receive Taxotere.
| Serious Effects |
["Severe hypersensitivity to docetaxel or any component of the formulation (e.g., polysorbate 80)","Neutrophil count < 1500 cells/mm³","Bilirubin > upper limit of normal (ULN)","AST/ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN"]
| Precautions | ["Neutropenia: Severe neutropenia with risk of febrile neutropenia and infection; monitor blood counts frequently.","Hypersensitivity reactions: Severe reactions including anaphylaxis can occur; premedicate with corticosteroids and antihistamines.","Fluid retention: Severe fluid retention including pleural effusion, pericardial effusion, and ascites; premedicate with corticosteroids.","Hepatotoxicity: Increased toxicity in patients with elevated LFTs; contraindicated if bilirubin > ULN or AST/ALT > 1.5 x ULN with ALP > 2.5 x ULN.","Peripheral neuropathy: Dose-related; assess neurological function.","Cardiotoxicity: Myocardial ischemia, arrhythmias; caution in patients with cardiac history.","Pulmonary toxicity: Interstitial pneumonitis, pulmonary fibrosis; discontinue if symptoms develop.","Extravasation: Tissue necrosis; avoid extravasation.","Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception."] |
Loading safety data…
| Fetal Monitoring | Monitor complete blood counts (CBC) weekly during pregnancy due to myelosuppression risk; fetal ultrasound every 4-6 weeks for growth restriction and anatomy; nonstress test and biophysical profile after viability; assess for signs of infection, bleeding, or fluid overload (hypersensitivity reactions). |
| Fertility Effects | Docetaxel is gonadotoxic. In females: May cause premature ovarian failure, reduced fertility, and menstrual irregularities; risk of permanent amenorrhea increases with cumulative dose and age >35 years. In males: Can induce azoospermia or oligospermia with potential irreversibility; sperm banking recommended prior to treatment. |